Resveratrol: a vital ingredient in healthy ageing
Evolva are committed to supporting high-quality clinical trials looking at the effects of resveratrol on humans. Below is an updated list of the trials we are currently supporting.
Published clinical studies using Evolva’s Veri-te™ resveratrol:
- Ornstrup, M. J., T. Harslof, T. N. Kjaer, B. L. Langdahl, and S. B. Pedersen. 2014. ‘Resveratrol increases bone mineral density and bone alkaline phosphatase in obese men: a randomized placebo-controlled trial’, Journal of Clinical Endocrinology and Metabolism, 99: jc20142799. View full published study here: Ornstrup 2014
- Poulsen, M.M., M.J. Ornstrup, T. Harslof, N. Jessen, B.L. Langdahl, B. Richelsen, J.O.L. Jørgensen, and S.B. Pedersen. 2014. ‘Short-term resveratrol supplementation stimulates serum levels of bone-specific alkaline phosphatase in obese non-diabetic men’, Journal of Functional Foods, 6: 305-10. View full published study here: Poulsen 2014
Ongoing clinical studies with Veri-te™ resveratrol sponsored or supported by Evolva:
- Study lead by Dr. P. Howe and Dr. R. Wong in U. Newcastle, Australia. 160 postmenopausal women, for 24 months. 150 mg/day of Evolva’s resveratrol. Focus on cardiometabolic, brain and bone health parameters. https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=370696
- Study lead by Dr. A. Duleba (UC San Diego, USA) and B. Banaszewska (Poznan Univ., Poland). 60 18-45 y/o women for 6 months. Simvastatin (20 mg) + Evolva’s resveratrol (500 mg) daily. Focus on Polycystic ovary syndrome (PCOS) and androgen levels. https://clinicaltrials.gov/ct2/show/NCT02766803
- Study led by Dr. V. Witte (Max Planck Institute, Leipzig, Germany). 60 subjects older than 60 y/o for 6 months. Evolva’s resveratrol (200 mg) + Quercetin (320 mg) daily. Focus on cognition via Learning Scores, MRI and biomarkers. https://clinicaltrials.gov/ct2/show/NCT02621554
- Study lead by Dr. H. Tenenbaum (U. Toronto, Toronto, Canada). 40 smokers with chronic periodontitis for 6 months. Resveratrol (500 mg) daily. Focus on periodontitis via biochemical and structural parameters.
- Study lead by Marcio Zaffalon Casati (U. Paulista, Sao Paulo, Brazil). 64 smokers for 6+6 months. Resveratrol (500 mg) daily. Focus on periodontitis via biochemical and structural parameters.
- Study lead by Nishant Gupta (U. of Cincinnati). 10 subjects with lymphangioleiomyomatosis (LAM) for 24 weeks. Combination of increased doses of resveratrol (250 mg to 1 g) with sirolimus/ rapamycin (2 mg) daily. Focus on safety and efficacy on LAM cells.
- Study lead by Emma Wightman (Northumbria University). 100 overweight and obese subjects for 12 weeks. Resveratrol (500 mg) in an acute dose and daily afterwards. Focus on microbiota, systemic inflammation and brain function. Scheduled to start by end 2017.